Skip to content

AGEPHAR

Active Private limited companyfounded 2023active for 2 yearsMarche, Rue du Commerce 32, 6900 Marche-en-FamenneKBO/BCE: BE 1002.549.933

Lifetime

2 annual accounts with figures on one time axis
peak of €141,002 in 2024
€115,662▼ 18.0%
peak of €2,379 in 2024
€387▼ 83.7%
peak of €22,766 in 2025
€22,766▲ 1.7%
€417,874▼ 6.3%
Board2 names since 2023
2 directors and 1 other
Documentsfilings and deeds
24-07-20267 days before the deadline
2025micro format
Gross margin from €141,002 to €115,662Result from €2,379 to €387

Key points

from the 2025 annual accounts

Overdue debts

€2,379 on 31-12-2025
Overdue tax debts
€1,369
Overdue social security (RSZ) debts
€1,009

The annual accounts state €1,369 of overdue tax debts and €1,009 of overdue social security (RSZ) debts on 31-12-2025.

Turnover

≈ €410,000 estimated

The micro format states no turnover.

Debts

€417,874 95% of the balance sheet
Financial debts 60%Suppliers 12%Taxes and wages 6%Other 23%

Of this, €159,287 falls due within a year.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,136 companies had the same profile as AGEPHAR has now. Each dot stands for 6 companies, two years later.

92.0%
were still trading
2.3%
stopped another way
5.2%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency under 10%
  • a profit under 5% of the balance sheet

Another 0.4% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,136 companies, not a prediction for AGEPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 22-11-2023
Director, since 22-11-2023
  • 51 sharesdeed of 24-11-2023
  • 49 sharesdeed of 24-11-2023
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:1002549933
Incorporation Founding capital of €20,000, 100 shares · Founded by and · (director) and (director) appointed · published on 24-11-2023 · Gazette deed
First establishment Marche, Rue du Commerce 32, Marche-en-Famenne
All 5 events

Comparable companies

same main activity, similar in size and age
Company
AGEPHAR Marche-en-Famenne €440,640 €115,662 5.2% -
PHARMACIE DE BERLOZ Berloz €466,197 €129,768 25.9% -
HUMAN PHARMA Charleroi €434,132 €114,557 51.8% 0.8
PHARMACIE DELVA Brussels €437,107 €104,836 11.8% -
SANA SP Staden €527,924 €116,582 72.5% -
PHARMACIE DES HAUTEURS Liège €512,962 €146,548 3.3% -
PHARMACIE DU PETIT MOULIN Seneffe €471,907 €114,484 4.9% -

These companies have the same main activity as AGEPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €434,000 and €528,000, founded between 2022 and 2024.

Official details

Source: KBO
Status
Active since 22-11-2023Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 1 other
Establishment unit
2.352.336.0136900 Marche-en-Famenne, since 22-11-2023
Financial year end
31 December
Peppol
Reachable since 22-12-2025
Company details

Annual accounts 2025

€440,640▼ 5.9%
Filing
Filed on 24-07-2026, 7 days before the end of the filing period
Financials

Insights on AGEPHAR

AGEPHAR has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €22,766 and a net result of €387.

Its solvency ranks better than 26% of 25,320 sector peers (NACE 47) in financial year 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about AGEPHAR

What is the company number of AGEPHAR?
The company number of AGEPHAR is 1002.549.933. The VAT number is the same number with BE in front: BE 1002.549.933.
Where is AGEPHAR based?
The registered office is at Marche, Rue du Commerce 32, 6900 Marche-en-Famenne.Company details
What does AGEPHAR do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of AGEPHAR?
AGEPHAR is a private limited company (BV).
When was AGEPHAR founded?
AGEPHAR was founded on 22-11-2023.
Is AGEPHAR still active?
Yes, AGEPHAR is an active enterprise in the KBO register.
How many employees does AGEPHAR have?
AGEPHAR had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of AGEPHAR?
The turnover in financial year 2025 is ≈ €410,000. This figure is estimated from the gross margin of €115,662 and 38 comparable companies (NACE 477). It probably lies between €310,000 and €670,000.
Is AGEPHAR profitable?
In financial year 2025, AGEPHAR made a profit of €387.
Where can I find the annual accounts of AGEPHAR?
AGEPHAR filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of AGEPHAR due?
AGEPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.